Drug intelligence / Profile preview

DAAP

Development stage: Preclinical
Lead developer: Aprogen
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Unknown

Overview

**DAAP** is a bispecific antibody developed by Aprogen that targets both angiopoietin-1 (Ang1) and vascular endothelial growth factor A (VEGF-A). Its mechanism is dual inhibition of Ang1 and VEGF-A signaling pathways, aiming to disrupt key drivers of angiogenesis and vascular stabilization. This approach is intended for the treatment of diseases involving pathological neovascularization and vascular permeability, such as neoplasms (cancers), congenital disorders, and eye diseases.

Brand names: DAAP
Other names: AP-202AP202AP 202

Targets

ANGPT2 (Angiopoietin-2)VEGFA (Vascular endothelial growth factor A)PGF (Placental Growth Factor)ANGPT1 (Angiopoietin-1)

Beyond the preview

Go deeper on DAAP.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DAAP.

Explore the full profile